Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 219-854-2 | CAS number: 2551-62-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Clinical study, acceptable for assessment of SF6 kinetics.
Data source
Reference
- Reference Type:
- publication
- Title:
- Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging
- Author:
- Morel DR
- Year:
- 2 000
- Bibliographic source:
- Investigative Radiology 35 (1): 80-5
Materials and methods
- Study type:
- clinical case study
- Endpoint addressed:
- basic toxicokinetics
Test material
- Reference substance name:
- Sulphur hexafluoride
- EC Number:
- 219-854-2
- EC Name:
- Sulphur hexafluoride
- Cas Number:
- 2551-62-4
- Molecular formula:
- F6S
- IUPAC Name:
- sulphur hexafluoride
- Test material form:
- solid - liquid: suspension
Constituent 1
Method
- Type of population:
- general
- Subjects:
- - Number of subjects exposed: 12
- Sex: 7 males / 5 females.
- Age: for the men, ages ranged from 24 to 36 years; for the women, ages ranged from 20 to 26 years.
- Body weight: men, 67 to 82 kg; women 56 to 69 kg.
- Height: men, 173-188 cm; women, 168-176 cm.
- Known diseases: none - healthy - Ethical approval:
- confirmed and informed consent free of coercion received
- Route of exposure:
- other: Intravenous administration
- Reason of exposure:
- intentional
- Exposure assessment:
- measured
- Details on exposure:
- SonoVue™ is a suspension of stabilized SF6 microbubbles in saline (0.9% sodium chloride). SonoVue™ was supplied as a sterile lyophilized powder (25 mg) in a gaseous atmosphere (SF6) in 10-mL vials. The SonoVue™ preparation was reconstituted just before administration by adding 5 mL sterile saline to the vial using standard clinical aseptic techniques. The bubble concentration is between 100 and 500 million per ml. Each milliliter contains approximately 13 μL of SF6 of which approximately 8 μL is encapsulated in the microbubbles and the remaining 5 μL is dissolved in the aqueous phase of the suspension.
SonoVue™ was administered intravenously as a bolus dose of 0.03 or 0.3 mL/kg in a large antecubital vein through a 20-gauge catheter.
Each of the 12 subjects received two injections of SonoVue™, with a minimum of 3 days and a maximum of 14 days in between. The two dosage levels, 0.03 and 0.3 mL/kg, were randomly ordered.. - Examinations:
- Clinical observations
pulse, blood pressure, electrocardiogram, lung function
Blood Sampling
Blood samples were collected predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 60, and 90 minutes after administration. Samples were collected using an indwelling catheter in a large forearm vein opposite to that used for SonoVue™ administration. Samples (3 mL) were collected anaerobically into K3EDTA-treated Vacutainer tubes (Becton Dickinson, Meylan, France) and were stored in the dark at room temperature before analysis.
Collection of Exhaled Air
Exhaled air samples were collected predose (-2–-1 minutes) and 0 to 0.5, 0.5 to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 6, 6 to 8, 8 to 11, 11 to 15, 15 to 20, 20 to 30, 45 to 55, and 80 to 90 minutes after administration. Exhaled air was collected through a respiratory mask and a pulmonary monitoring system (Spirobank, MIR Srl, Rome, Italy) into Tedlar bags (SKC Inc., PA). The pulmonary monitoring system recorded the volume of air exhaled during each sampling period. Subjects were asked to exhale normally and continuously into plastic bags, which were changed at intervals. Sampling bags were connected to a two-way valve system to allow instantaneous switching from one bag to another; therefore, at no time were subjects asked to hold their breath. After collection of all samples for an individual subject, the bags containing expired air were stored at room temperature before analysis, which was carried out within 1 to 4 days.
Results and discussion
- Clinical signs:
- No clinically significant changes were observed in vital signs, clinical laboratory parameters, or physical examination during the study. No adverse effects were observed or reported immediately or during the 24-hour follow-up period. Four subjects (33.3%) reported six local heat or pain sensations at the injection site immediately after the injection. No subjects reported local heat or pain 5 minutes after the injection.
- Results of examinations:
- Details on absorption: Median blood concentrations of SF6 peaked 1 to 2 minutes after injection of both dosage levels in both men and women. After reaching the maximum blood concentration, SF6 rapidly declined.
Details on excretion: Pulmonary elimination of SF6 was extremely rapid. Within 1 minute after administration, approximately 39% to 45% (men) and 43% to 47% (women) of the administered doses (0.03 and 0.3 mL/kg, respectively) was eliminated with the exhaled air
Any other information on results incl. tables
Details on absorption:
Median blood concentrations of SF6 peaked 1 to 2 minutes after injection of both dosage levels in both men and women. After reaching the maximum blood concentration (Cmax), SF6 rapidly declined. The decline was monophasic for the 0.03-mL/kg dose and biphasic for the 0.3-mL/kg dose. For the 0.03-mL/kg dose, median blood concentrations of SF6 were approximately 20% and 13% of Cmax at 4 minutes after administration for men and women, respectively. For the 0.3-mL/kg dose, median blood levels of SF6 were approximately 6% and 16% of Cmax at 6 minutes after administration for men and women, respectively. Blood levels of SF6 were not detected or were below the lower limit of quantification at 12 minutes after administration for most of the subjects receiving the 0.03-mL/kg dose and at 60 minutes after administration for those receiving the 0.3-mL/kg dose.
Details on excretion:
Pulmonary elimination of SF6 was extremely rapid. Within 1 minute after administration, approximately 39% to 45% (men) and 43% to 47% (women) of the administered doses (0.03 and 0.3 mL/kg, respectively) was eliminated with the exhaled air. By 11 minutes after administration, 81% to 84% (men) and 78% to 89% (women) of the administered doses was eliminated by the pulmonary route for both dosage levels. The fraction of the administered dose eliminated in the expired air was thus similar for men and women and was independent of dose. Within 90 minutes, SF6 could no longer be detected in the expired air in most of the subjects for both dosage levels.
Applicant's summary and conclusion
- Conclusions:
- It was concluded that, under the test conditions, human exposure to SF6 did not result in any adverse effects. No clinically significant changes were observed in vital signs, clinical laboratory parameters, or physical examination during the study. SF6 was rapidly removed from the blood. The route of SF6 elimination was as parent compound by means of the lungs in the expired air. The extremely rapid pulmonary elimination of the compound would indicate that SF6 does not accumulate in healthy subjects, even with repeated administration.
- Executive summary:
A clinical study was conducted in 12 healthy subjects (7 men, 5 women) to evaluate the blood kinetics and pulmonary elimination of sulphur hexafluoride after intravenous bolus injection of two dosage levels (0.03 and 0.3 mL/kg) of SonoVue™. In addition, safety and tolerability were evaluated by monitoring vital signs, adverse effects, discomfort, and physical examination and laboratory parameters associated with the SonoVue™ injection.
The blood kinetics of SF6 was not dose dependent. SF6 was rapidly removed from the blood by the pulmonary route, with 40% to 50% of the injected dose eliminated within the first minute after administration and 80% to 90% eliminated by 11 minutes after administration; the elimination was similar in men and women and independent of dose. Both dosages were well tolerated. No adverse effects were observed immediately or during the 24-hour follow-up period.
Based on the results of this study, it could be concluded that SF6 was rapidly removed from the blood. The route of SF6 elimination was as parent compound by means of the lungs in the expired air. The extremely rapid pulmonary elimination of the compound would indicate that SF6 does not accumulate in healthy subjects, even with repeated administration.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.